Health Care · S&P 500
Gilead Sciences
A biopharmaceutical company developing HIV and hepatitis therapies, leading the antiviral drug field. S&P 500 constituent. Sector: Health Care (Biotechnology). Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
GILD Updated Jul 11, 2026 2 AI consumers
Annual return · 2026-07-10'21+30%'22+23.6%'23-2%'24+18.7%'25+36.6%YTD+7.1%
Money in ▸·
Gilead Sciences~$28.8B
▸ Money out·
Financials & Segments
- Total revenue · ~$28.8B (FY2024)
- Segments · HIV · Liver Disease · Oncology & Cell Therapy
Revenue from
No refined links yet.
Pays to
No refined links yet.